Acute kidney injury associated with endurance events—is it a cause for concern? A systematic review

LE Hodgson,1 E Walter,2 RM Venn,1 R Galloway,3 Y Pitsiladis,2 F Sardat,4 LG Forni2,5

ABSTRACT

Introduction A growing body of evidence suggests even small rises in serum creatinine (SCr) are of considerable clinical relevance. Given that participants in endurance events are exposed to potential (repeated) renal insults, a systematic review was undertaken to collate current evidence for acute kidney injury (AKI), complicating such events.

Methods A systematic review of studies and case reports meeting inclusion criteria on Medline and EMBASE (inception to October 2015). Included: studies with markers of renal function before and after endurance or ultraendurance events; case reports of severe AKI. Two reviewers assessed risk of bias using the Newcastle-Ottawa scale.

Results Eleven case report publications (n=27 individuals) of severe AKI, were retrieved, with risk factors including systemic illness or nephrotoxic medications usually identified. From 30 studies of endurance and ultraendurance events, mean rise in SCr was 29 (±12.3) µmol/L after marathon or ultramarathon (17 studies, n=568 participants) events. Where follow-up tests were conducted, SCr returned to baseline within 48 hours. Rises in biomarkers suggest potential parenchymal insult, rather than simply muscle breakdown. However, evidence of long-term deleterious effects is lacking.

Conclusions Raised levels of SCr are reported immediately after endurance events. It is not clear whether this is either clinically significant, or if repeated participation predisposes to long-term sequelae. The aetiology of severe exercise-associated AKI is usually multifactorial, with risk factors generally identified in the rare cases reported. On-site biochemistry, urine analysis and biomarkers of AKI may help identify collapsed runners who are at significant short-term risk and allow suitable follow-up.

INTRODUCTION

Endurance events continue to increase in popularity. For example, marathon participation in the USA has risen from 25 000 in 1976 to over half a million in 2011.1 Participation in ultramarathons (a running event involving a distance longer than the traditional marathon length)2 is also rapidly growing. Although individuals who exercise regularly have lower rates of disability and a mean life expectancy some 6 years longer than that of their less active contemporaries, there remain some concerns regarding potential adverse sequelae.3–5 Although sudden death among athletes attracts much publicity, it is rare and often due to a pre-existing cardiomyopathy.6–9 More commonly, less severe organ damage may occur during strenuous exercise, which, if repeated over time, could have long-term significance, including renal damage, as evidenced by animal studies10 and human studies investigating cardiac imaging and enzyme markers.11–19 Though long-term evidence of harm remains scarce, recent studies have suggested an attenuation of the benefits of exercise, among those performing the most strenuous exercise, with a J-shaped or U-shaped association between all-cause mortality and running dose.20–22

Quantifying renal damage and defining renal failure has, until recently, suffered
from a lack of consensus definition. However this has been addressed, in part, by the adoption of the concept of acute kidney injury (AKI) which classifies renal injury on the basis of changes in measured serum creatinine (SCR) compared with baseline values and/or changes in monitored urine output (see Appendix for AKI definitions). This has allowed classification of patients, particularly in acute settings such as the critical care environment, allowing comparison between groups, as well as defining renal injury, which may not progress to renal failure requiring extracorporeal support. Of particular relevance is the observation that what was previously viewed as relatively trivial increases in SCR, carries an increase in acute mortality. It is now clear that renal injury, as defined by AKI, puts patients at longer-term risks of both morbidity and mortality.

The earliest studies reporting urinary changes on extreme exercise coincided with the seminal work by Bywaters and Beall describing the biochemical and histopathological features of crush injury observed in air raid victims during World War II which we now describe as rhabdomyolysis. The first documented study in athletes was in 1941 and described myoglobinuria, haematuria and albuminuria in marathon runners with the first case reports of acute renal failure complicating any sporting event reported in the 1960s. Within the clinical arena there are numerous potential specific causes of AKI but a number of factors alone, or in combination, may exacerbate the condition. These include volume depletion secondary to inadequate fluid intake and excessive losses, rhabdomyolysis and the use of drugs such as non-steroidal anti-inflammatory drugs (NSAIDs). It follows that these factors may be common to individuals competing in endurance events with the further potential complications of climate and exercise-associated heat stroke (EHS). Therefore, AKI may be a more common complication of endurance events than anticipated. While this may seem a relatively harmless ‘side-effect’ of endurance events, there is now a considerable body of evidence that points to the fact that an episode of AKI complicating critical illness, for example, carries a significant risk of longer-term mortality and morbidity. Could this observation be relevant to those exhibiting an SCR rise after endurance events?

Research questions
To systematically review the frequency of AKI associated with endurance (and ultraendurance) events; to quantify changes in SCR as a marker of renal dysfunction in endurance event studies recording values pre-event and postevent. Furthermore, the review will explore mechanisms of renal dysfunction due to exercise-associated rhabdomyolysis and use of NSAIDs; finally future studies, including the use of renal biomarkers, will be addressed.

Rationale and objectives
Endurance event participation is increasing and emerging evidence suggests extreme exercise could potentially attenuate some of the benefits seen with regular exercise. AKI is an independent contributor to mortality in a large number of clinical settings. There have been case reports of significant AKI requiring hospital care following endurance events and also prospectively studied markers of renal dysfunction following endurance events, but to date, there has been no systematic review of this field. Thus, the rationale for this review was to collate all empirical evidence for AKI in endurance (and ultraendurance) events, fitting the prespecified eligibility criteria for inclusion, to answer the research questions. Explicit, systematic methods were selected with a view to minimising bias and provide reliable findings from which conclusions can be drawn.

METHODS
Inclusion criteria
Adult human studies in the English language in peer-reviewed journals, of endurance or ultraendurance events, examining markers of renal function; to quantify a change in SCR, studies would be included where an SCR value pre-event and immediately post the event was reported, though studies without both values would also be reported; case report studies of participants with AKI requiring hospitalisation following an endurance event.

Exclusion criteria
Research involving paediatric patients (<18 years old) and non-human studies; studies involving events not considered endurance (eg, <1 hour), such as track and field or football.

Identification, screening, risk of bias
We searched Medline and EMBASE for English language articles from inception to October 2015 with the text words and related Medical Subject Headings terms: ‘AKI,’ ‘acute kidney injury,’ ‘Acute renal failure,’ ‘Renal’ and ‘Marathon’ or ‘Endurance events’ as the initial set of search terms; to ensure a comprehensive literature search, reference lists were examined from retrieved articles (see Appendix for search string and PRISMA flow diagram). Titles and abstracts were screened and full articles reviewed if thought to be eligible for inclusion. Data extraction (using a pretested form), study design and quality were performed by two investigators. Discrepancies in any data extraction were discussed and assessment of a third reviewer was sought for resolution. Two reviewers assessed the risk of bias of each study using the Newcastle-Ottawa Scale. This scale awards a maximum of nine stars across three domains (selection, comparability of cohorts on the basis of the design and...
Mean fractional sodium and uric acid hence the use of SCr to investigated renal function up and 2 10 ultramarathons 24—35 48–59 Eight participants had and six 3 an Ironman, 2 half-marathons, 45–47 Eight participants had collapsed during the event. The majority (21/27) presented to medical attention in a delayed fashion—sometimes over a week after the event. In two-thirds of cases (18/27), a history of NSAID before and/or during the event was elicited. Other risk factors included recent illness and vomiting during the events. Fifteen cases required temporary dialysis. A renal biopsy was performed on only four occasions, with features of acute tubular necrosis (ATN) in all the biopsies, suggesting an ischaemic aetiology. A diagnosis of rhabdomyolysis was made, or presumed, in 85% (n=23) of the cases. Where reported, follow-up renal function was required temporary dialysis. A renal biopsy was performed on only four occasions, with features of acute tubular necrosis (ATN) in all the biopsies, suggesting an ischaemic aetiology. A diagnosis of rhabdomyolysis was made, or presumed, in 85% (n=23) of the cases. Where reported, follow-up renal function was reported to be normal, with no requirement for long-term renal replacement therapy.

A total of 30 studies (n=1724 participants) on renal function in endurance events were identified (table 1). Of the events, five were marathons, 46–44 and six ultramarathons. 45 47 Eight participants had collapsed during the event. The majority (21/27) presented to medical attention in a delayed fashion—sometimes over a week after the event. In two-thirds of cases (18/27), a history of NSAID before and/or during the event was elicited. Other risk factors included recent illness and vomiting during the events. Fifteen cases required temporary dialysis. A renal biopsy was performed on only four occasions, with features of acute tubular necrosis (ATN) in all the biopsies, suggesting an ischaemic aetiology. A diagnosis of rhabdomyolysis was made, or presumed, in 85% (n=23) of the cases. Where reported, follow-up renal function was reported to be normal, with no requirement for long-term renal replacement therapy.

A total of 30 studies (n=1724 participants) on renal function in endurance events were identified (table 1). Of the events, five were marathons, and six ultramarathons, 46–44 2 half-marathons, 49 an Ironman, 2 a 24-hour marathon relay, 50 73 a 60-km mountain run and 1 ultramarathon cycle races. 51 76 Of 21 foot race events (n=800 participants) reporting pre-event and post-event SCr levels, 17 were studies of marathons or ultramarathons (n=568 participants). For risk of bias, 26 of the studies were deemed of good quality with a Newcastle-Ottawa Score of at least seven stars (see supplementary table for full details).

Creatinine production and clearance
A proportion of the SCr rise observed on extreme exercise reflects increases in muscle breakdown, with an enhanced solute load, rather than a fall in glomerular filtration rate (GFR). 54 Hence the use of SCr to estimate GFR (eGFR) under conditions of extreme exercise should be avoided. Interestingly, a study on six marathon runners demonstrated that on the 1st day after the race, creatinine clearance actually increased, peaking on day 3 with increased urine flow rates on all 5 days postrace. 35 This reflects the concept of augmented renal clearance, which is in fact a normal response to increased tubular flow. Rates of excretion and production of creatinine were closely matched on all study days. 35 These results are in contrast to a study which showed no change in creatinine clearance, although insulin clearance reduced by 50% and further studies in ultramarathon cyclists where a decline in creatinine clearance of 18—25% was observed. 73 76 Mean fractional sodium and uric acid excretion also fell, which may indicate reduced renal perfusion, and SCr rose by 20–36%, returning to normal at 24 hours.

Rises in SCr
Across 21 studies (n=800) where pre-event and post-event SCr levels were available, mean SCr increase was 25.7 (±11.6) μmol/L. Of the 17 marathons or ultramarathons described (n=568), mean SCr increase was 29 (±12.3) μmol/L, above the threshold for AKI stage 1. 24 Though most studies demonstrated an increase in SCr immediately following the event, in the 13 studies reporting recovery of function, as described by changes in SCr, all had returned to baseline or were improving within 48 hours (table 2). Studies involving half-marathons reported smaller increases in SCr levels, with eGFR recovering within 6 hours in one study. 77 In two recent extended ultraendurance races over weeks to months, no contestants developed AKI, despite significant rises in CK, suggesting repetitive, relatively lower intensity exercise, despite the large total distance covered, may mean that cumulative damage does not occur in these events. 77 78 A recent study by Lipman et al also supports this, documenting rises in SCr, with 45–67% meeting RIFLE criteria 'Risk' and 7–13% ‘Injury’ (see Appendix for RIFLE criteria) between stages of a multistage ultramarathon race, but found a rapid reduction back to baseline prior to the following stage. Christensen et al investigated renal function up to 48 hours following a 78-km ultramarathon at moderate altitude (~2400 m) by 10 runners from the Mexican Tarahumara tribe, who have maintained the once widespread tradition of ultradistance running, from a young age. The authors found immediate post-race SCr was not significantly elevated, though an increase of 25% was noted by 6 hours, with a subsequent fall-back to baseline at 48 hours. Follow-up for the 30 studies did not extend beyond more than a few
Table 1  Summary of 11 case reports of 27 athletes with AKI following a marathon or ultramarathon

<table>
<thead>
<tr>
<th>Study</th>
<th>Cases</th>
<th>Collapse</th>
<th>Delayed</th>
<th>Type</th>
<th>NSAIDs</th>
<th>Dialysis</th>
<th>Risk factors</th>
<th>SCr (μmol/L)</th>
<th>CK (U/L)</th>
<th>Urine</th>
<th>Follow-up</th>
<th>Biopsy</th>
<th>Diagnosis / comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dancaster, 1969</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>Ultramarathon</td>
<td>Both took an analgesic</td>
<td>-</td>
<td>Case 1: moderate albumin; Case 2: 2+ protein, RBCs and granular casts; spectral exam -ve for blood and myoglobin; occult test for blood +ve</td>
<td>-</td>
<td>-</td>
<td>Case 1:1 year</td>
<td>115 mL/min</td>
<td>Rhabdomyolysis.</td>
<td>Case 2 had markedly elevated AST, ALT, LDH</td>
</tr>
<tr>
<td>Pollard 1970</td>
<td>1</td>
<td>1</td>
<td></td>
<td>Marathon</td>
<td>-</td>
<td></td>
<td>Reported recurrent haematuria postexercise</td>
<td>1193</td>
<td>72 hours</td>
<td>3+ RBCs, granular casts; spectroscopy -ve for free haemoglobin and myoglobin</td>
<td>Renal function 'normal' at 4/52</td>
<td>ATN</td>
<td>March Haemoglobinuria? Bilateral flank pain</td>
</tr>
<tr>
<td>MacSearraigh, 1979</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>Ultramarathon</td>
<td>5</td>
<td>5</td>
<td>Diarrhoea (1), Vomiting (3), EHS (1), recent illness (3) Hypertension (2)</td>
<td>28 000</td>
<td></td>
<td>Case 4: normal CrCl.</td>
<td>6 years ATN</td>
<td>Case 4</td>
<td>ATN and old fibrosis</td>
</tr>
<tr>
<td>Bar-Sela, 1979</td>
<td>1</td>
<td>1</td>
<td></td>
<td>Marathon</td>
<td>1</td>
<td></td>
<td>Recent flu-like illness</td>
<td>10 400</td>
<td></td>
<td>Proteinuria, RBCs, granular casts; -ve for myoglobin</td>
<td>normal CrCl 6/12</td>
<td>Case 8</td>
<td>ATN and old fibrosis</td>
</tr>
<tr>
<td>Goldsmith, 1984</td>
<td>1</td>
<td>1</td>
<td></td>
<td>Marathon</td>
<td>1</td>
<td></td>
<td>253 1/52 post</td>
<td>Weakly +ve for RBCs</td>
<td></td>
<td>Full recovery 6/52</td>
<td>Rhabdomyolysis (presumed)—stiff leg muscles, lumbar pain to groins, polydipsia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Cases</td>
<td>Collapse</td>
<td>Delayed</td>
<td>Type</td>
<td>NSAIDs</td>
<td>Dialysis</td>
<td>Risk factors</td>
<td>SCr (μmol/L)</td>
<td>CK (U/L)</td>
<td>Urine</td>
<td>Follow-up</td>
<td>Biopsy</td>
<td>Diagnosis / comments</td>
</tr>
<tr>
<td>---------------------</td>
<td>-------</td>
<td>----------</td>
<td>---------</td>
<td>------------</td>
<td>---------</td>
<td>----------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------</td>
<td>-------------------------------</td>
<td>-----------</td>
<td>--------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Vitting, 1986</td>
<td>1</td>
<td>1</td>
<td></td>
<td>Marathon</td>
<td>1</td>
<td>1</td>
<td>Hypertension</td>
<td>1025</td>
<td>83</td>
<td>1+ protein, 1+ RBC, scattered</td>
<td>Day 26</td>
<td></td>
<td>Scr 106</td>
</tr>
<tr>
<td>Seedat, 1989</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>Ultramarathon</td>
<td>4</td>
<td>3</td>
<td>Recent UTI, Influenza</td>
<td>Case 1: 930</td>
<td>1: 39800</td>
<td>2: 604, 3: 593, 4: 1263</td>
<td>Not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le Meurl, 1998</td>
<td>1</td>
<td>1</td>
<td></td>
<td>Marathon</td>
<td>1</td>
<td></td>
<td>Recurrent haematuria on exercise; frank haematuria in race</td>
<td>1,070</td>
<td>233</td>
<td>RBC count 4 × 10^6/mL; haemoglobinuria slightly +ve; myoglobinuria -ve</td>
<td>Full recovery</td>
<td>2/12</td>
<td>ATN</td>
</tr>
<tr>
<td>van Zyl-Smit, 2000</td>
<td>1</td>
<td>1</td>
<td></td>
<td>Ultramarathon</td>
<td>–</td>
<td></td>
<td></td>
<td>713, 10 days post</td>
<td>–</td>
<td>2+ protein 1+ blood, moderate granular casts</td>
<td>Full recovery</td>
<td></td>
<td>Rhabdomyolysis (presumed)</td>
</tr>
<tr>
<td>Bruso, 2010</td>
<td>3</td>
<td>3</td>
<td></td>
<td>Ultramarathon</td>
<td>–</td>
<td></td>
<td>Case 1: vomiting, Case 1 and 3 required intravenous fluid post race</td>
<td>Case 1: 911</td>
<td>7 85250</td>
<td>Case 2: 38 218, Case 3: &gt;40 000</td>
<td>All rhabdomyolysis</td>
<td></td>
<td>Case 1: 12 days in hospital; 2: 3 days in hospital; 3: 1 day in hospital 2 presented 24 hours; 1 presented 48 hours; all hyponatraemic (range 129-134)</td>
</tr>
</tbody>
</table>
days, thus conclusions around the effects of recurrent participation in such events cannot be made.

**Studies examining the use of NSAIDs**

In the studies where NSAID use was reported, 23% (n=312/1359) of participants admitted to NSAID usage. Two studies, one of marathon runners and another of 330 Ironman participants, reported a significant increase in Scr in the participants using an NSAID. In contrast, a prospective ultramahon study Dunke et al studied a group taking an NSAID (n=29) and a group not (n=25) with no significant difference in Scr between groups.

**Studies on collapsed runners**

Two studies specifically reported on Scr levels in runners who had collapsed. In the first, 36 collapsed runners had mean postrace Scr of 141 (±26) vs 123 (±23) μmol/L in a control group of 60 runners (p<0.01). Within 24 hours, mean Scr had fallen to 104 (±13) μmol/L compared with 95 (±13) μmol/L in the control group (p<0.05). Irving et al included eight ultra-marathon runners who had collapsed with hyponatraemia (<130 mmol/L) requiring hospital admission. Their postrace mean Scr level was 89 μmol/L vs 104 μmol/L in a control group (n=18). A repeat test on ‘recovery’ showed mean Scr levels had reduced to 68 μmol/L (p<0.05) and 78 μmol/L (p<0.01), respectively.

**Other markers of possible renal dysfunction**

The Scr provides the basis by which chronic kidney disease (CKD) is defined, with the eGFR allowing stratification of patients with CKD. However, the use of Scr, and derived eGFR equations implies that creatinine production rate is at a steady state and hence, more accurately reflects the GFR. This is not the case in many acute clinical scenarios and clearly not during and after, extreme exercise. The use of other candidate molecules as potential markers of renal dysfunction is emerging as a potential avenue to investigate the true significance of endurance events on renal function—particularly in the higher-risk group of participants who have collapsed. Any potentially useful candidate AKI biomarker(s) should ideally fulfil several criteria. These include, the provision of information above that currently available in determining abnormal renal function and also distinguish prerenal azotaemia from intrinsic renal disease. This is of particular relevance in extreme exercise where a prerenal component may predominate. If biomarkers could aid prognostication regarding potential renal recovery this also would be beneficial. Most recently identified biomarkers of AKI can be broadly classified into three groups: low molecular weight proteins which undergo glomerular filtration and hence reflect glomerular function, or markers of tubule damage, such as enzymes released.
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Event</th>
<th>n</th>
<th>Collapse</th>
<th>NSAID</th>
<th>Prerace SCr (μmol/L)</th>
<th>Postrace SCr</th>
<th>Repeat SCr</th>
<th>Mean SCr rise</th>
<th>Additional markers and notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riley</td>
<td>1975</td>
<td>Marathon</td>
<td>5</td>
<td>2</td>
<td></td>
<td>94 (±2)</td>
<td>136 (±6)</td>
<td></td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Noakes</td>
<td>1976</td>
<td>Ultramarathon</td>
<td>13</td>
<td></td>
<td></td>
<td>97</td>
<td>128</td>
<td></td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Neviackas</td>
<td>1981</td>
<td>Marathon</td>
<td>6</td>
<td></td>
<td></td>
<td>84 (range 70–97)</td>
<td>6 hours: 104 (70–159)</td>
<td>1 week: 86 (62–97)</td>
<td>20</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Irving</td>
<td>1986</td>
<td>Marathon</td>
<td>6</td>
<td></td>
<td></td>
<td>89 (±3)</td>
<td>96 (±5)</td>
<td></td>
<td>7</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Kraemer</td>
<td>1986</td>
<td>Marathon</td>
<td>20</td>
<td></td>
<td></td>
<td>80 (±17)</td>
<td>120 (±20)</td>
<td></td>
<td>40</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Irving</td>
<td>1989</td>
<td>24 hour relay marathon</td>
<td>2</td>
<td></td>
<td></td>
<td>81, 86</td>
<td>101, 119</td>
<td></td>
<td>20, 33</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Nelson</td>
<td>1989</td>
<td>Marathon</td>
<td>38</td>
<td></td>
<td></td>
<td>81</td>
<td>123</td>
<td></td>
<td>42</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Borkowski</td>
<td>1990</td>
<td>Marathon</td>
<td>6</td>
<td></td>
<td></td>
<td>55</td>
<td>66 (±8); 53</td>
<td></td>
<td>6, 13 (collapsed)</td>
<td>Urine PCR x 2.6 higher postrace; increase trypsin inhibitor: creatinine ratio at 6–18 hours</td>
</tr>
<tr>
<td>Irving</td>
<td>1990a</td>
<td>Ultramarathon</td>
<td>5</td>
<td>1</td>
<td></td>
<td>42; normal 63 (±3)</td>
<td>55 collapsed, normal 69 (±10)</td>
<td>66 (±8); 53</td>
<td>6, 13 (collapsed)</td>
<td>Urine PCR x 2.6 higher postrace; increase trypsin inhibitor: creatinine ratio at 6–18 hours</td>
</tr>
<tr>
<td>Irving</td>
<td>1990b</td>
<td>Ultramarathon</td>
<td>8</td>
<td></td>
<td></td>
<td>91</td>
<td>110</td>
<td></td>
<td>'normal' 19</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Irving</td>
<td>1991</td>
<td>Ultramarathon</td>
<td>26</td>
<td>8</td>
<td>3</td>
<td>Collapsed 88.9 (±8), Controls 104 (±5)</td>
<td>Collapsed 68, Controls 78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holtzhausen</td>
<td>1994</td>
<td>Marathon</td>
<td>96</td>
<td>36</td>
<td></td>
<td>Collapsed 141 (±26), Controls 123 (±23)</td>
<td>24 hours: Collapsed 104 (±13), Control 95 (±13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kratz</td>
<td>2002</td>
<td>Marathon</td>
<td>37</td>
<td></td>
<td></td>
<td>88</td>
<td>115</td>
<td></td>
<td>27</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
<tr>
<td>Neumayr</td>
<td>2003</td>
<td>Ultramarathon cycle</td>
<td>38</td>
<td></td>
<td></td>
<td>88</td>
<td>106</td>
<td></td>
<td>18</td>
<td>6 hours: 104 (70–159); 1 week: 86 (62–97)</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Event</th>
<th>n</th>
<th>Collapse</th>
<th>NSAID</th>
<th>Postrace SCr (µmol/L)</th>
<th>Repeat SCr</th>
<th>Mean SCr rise</th>
<th>Additional markers and notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reid</td>
<td>2004</td>
<td>Marathon</td>
<td>134</td>
<td>18</td>
<td>M 110, F 100 (50–160)</td>
<td>83 (±15)</td>
<td>111 (±19)</td>
<td>26</td>
<td>NSAID group had higher SCr (p=0.01)</td>
</tr>
<tr>
<td>Neumayr</td>
<td>2005</td>
<td>Ultramarathon cycle</td>
<td>16</td>
<td>84 (±15)</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Wharam</td>
<td>2006</td>
<td>Ironman triathlon</td>
<td>333</td>
<td>100</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Page</td>
<td>2007</td>
<td>60-km mountain run</td>
<td>123</td>
<td>43</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Dumke</td>
<td>2007</td>
<td>Ultramarathon</td>
<td>54</td>
<td>29</td>
<td>NSAID 85 (±12), controls: 91 (±15)</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Lippi</td>
<td>2008</td>
<td>Half-marathon</td>
<td>17</td>
<td>99 (90–113)</td>
<td>NSAID 118, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Mingels</td>
<td>2009</td>
<td>Marathon</td>
<td>70</td>
<td>86*</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>McCullough</td>
<td>2011</td>
<td>Marathon</td>
<td>25</td>
<td>80 (±3)</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Mohseni</td>
<td>2011</td>
<td>Half-marathon</td>
<td>195</td>
<td>78</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Mydlak</td>
<td>2012</td>
<td>Half or marathon</td>
<td>49</td>
<td>93 (±10)</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Lippi</td>
<td>2012</td>
<td>Ultramarathon</td>
<td>16</td>
<td>68 (58–76)</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Hoffman</td>
<td>2013</td>
<td>Ultramarathon</td>
<td>107</td>
<td>70</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Lipman</td>
<td>2014</td>
<td>Ultramarathon</td>
<td>30</td>
<td>88 (±18)</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Christensen</td>
<td>2014</td>
<td>Ultramarathon</td>
<td>10</td>
<td>60</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
<tr>
<td>Hou</td>
<td>2015</td>
<td>Ultramarathon</td>
<td>26</td>
<td>2</td>
<td>NSAID 130, controls 120</td>
<td>100 (50–160)</td>
<td>111 (±19)</td>
<td>26</td>
<td>Significant increase in NSAID group versus no NSAID (p=0.01)</td>
</tr>
</tbody>
</table>
into the urine after tubular cell injury, or inflammatory mediators either released by renal cells, or by infiltrating inflammatory cells.

Cystatin C is an effective biomarker of glomerular filtration, correlates well with GFR and is independent of muscle mass. Indeed, studies on renal function following strenuous exercise demonstrated that the mean cystatin C rise was half that of the mean SCr rise in runners following a marathon. Further studies demonstrated a correlation between cystatin C and SCr rise immediately after a marathon, with 40% of participants reaching the creatinine criteria for stage 1 AKI. Participants also demonstrated a rise in urinary neutrophil gelatinase-associated lipocalin (NGAL) and urinary kidney injury molecule-1 (KIM-1), suggesting early tubular dysfunction, although all biomarkers returned to baseline within 24 hours. Hewing in a Berlin marathon study (n=167), found cystatin-based GFR was significantly decreased by RIFLE criteria, with 30% demonstrating a decrease of >25% (risk) and 8% a decrease >50% (injury). All parameters returned to baseline ranges within a 2-week follow-up period.

NGAL is a 25 kDa acute phase protein largely produced by the kidney tubule, though it is also upregulated in other pathological conditions. In a study of 16 ultramarathon runners, mean increase in SCr was 38%, with a significant increase in serum NGAL, urinary NGAL, as well as the urinary NGAL/creatinine ratio. Other studies have demonstrated increases in the urine protein:creatinine ratio 6–18 hours postrace. In a study on 152 runners in a 161 km ultramarathon, 34% met AKI criteria, with those demonstrating more significant degrees of injury having a significantly higher CK concentration. In addition, urinalysis tests that were positive for at least 1+ protein, 3+ blood and specific gravity ≥1.025 predicted those meeting the injury criteria with high sensitivity. The authors commented that using this simple test could be a useful screening test to identify those at highest rise.

The diagnostic utility of most of the biomarkers described to date to diagnose AKI prior to elevations in SCr is variable. This is due, in part, to clinical studies being hampered by diverse patient populations with differing comorbidities, the timing of the measurements and chosen cut-off values. More recently, studies have emerged using two biomarkers associated with cell cycle arrest, namely insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2. The concentrations of these two proteins was found to be in the urine of patients at high risk of AKI from a variety of aetiologies. Initial studies seem to suggest that these perform better than other known markers within this patient cohort; the mechanism of which may be an ‘alarm signal’ raised by the renal tubules, in response to stress. Furthermore, recent data imply that the presence of these biomarkers in the context of AKI may predict a worse prognosis in the critically ill, so perhaps they may be able to identify a

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Continued</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Event</strong></td>
<td><strong>n</strong></td>
</tr>
<tr>
<td>Marathon</td>
<td>167</td>
</tr>
<tr>
<td>Mean values (±SD), unless stated,* Median (IQR). AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; F, female; M, male; NGAL, neutrophil gelatinase-associated lipocalin; NSAID, non-steroidal anti-inflammatory drug; PCR, protein:creatinine ratio; sNGAL, serum NGAL; SCr, serum creatinine; uNGAL, urine NGAL.</td>
<td>Hodgson LE, et al. BMJ Open Sport Exerc Med 2017;3:e000093. doi:10.1136/bmjsem-2015-000093</td>
</tr>
</tbody>
</table>
group of athletes who may require closer follow-up (see figure 1 for a pathway outlining the aetiology of endurance exercise related renal dysfunction and potential utility of a biomarker to risk stratify participants). Non-steroidal anti-inflammatory drugs

NSAIDs inhibit cyclo-oxygenase, thereby preventing prostaglandin synthesis (PGs). PGs enhance renal perfusion through vascular dilatation and promote diuresis and natriuresis through inhibition of sodium transport in the thick ascending limb of loop of Henle and the collecting ducts. \( \text{PGE}_1 \) tends to antagonise the action of vasopressin and \( \text{PGI}_2 \) in concert with \( \text{PGE}_2 \) serves to maintain the GFR. In healthy subjects, basal renal vasoconstrictor tone is low and the vasodilation produced by PGs is not required for normal renal function. In disease states however, where increased sympathetic outflow to the kidney may be found, PGs vasodilate the renal vascular bed and ensure adequate renal blood supply. Therefore inhibition of PG synthesis may result in the unopposed vasoconstrictive action of leukotrienes, angiotensin II, vasopressin, endothelin and catecholamines. Indeed, NSAIDs have been shown to decrease renal blood flow with exercise, although this did not translate into significant differences in GFR (measured by inulin clearance) when subjects exercised at 80% \( \text{VO}_{2\text{max}} \) for 30 min. Olsen et al studied healthy volunteers undergoing submaximal exercise with and without indomethacin. This NSAID significantly inhibited renal PG synthesis and renin release. Overall renal functional response to exercise remained unchanged, possibly because of inhibition of renin-mediated angiotensin II generation and cyclo-oxygenase-1 mediated thromboxane \( \text{A}_2 \) synthesis.

Given that NSAIDs may have deleterious effects on renal blood flow, does the use of these agents translate into a higher risk of AKI in subjects undergoing extreme exercise? To date, few studies have addressed the impact of NSAID use on renal function after an endurance event, compared with those not taking NSAIDs. Reid et al found a significant mean increase in creatinine in the NSAID group compared with those not taking an NSAID in marathon runners. Wharam et al, in an Ironman study, reported a statistically significant difference in SCr of 10 \( \mu \text{mol/L} \) among the NSAID group, though this may not suggest a clinically significant difference. In contrast, Dumke et al, in a prospective study, found no significant difference in markers of renal function between those who did, and did not, use NSAIDs. However, our review data presented here show that 18 of the 27 case reports (67%) of renal failure (requiring hospital treatment) following an endurance event had taken an NSAID, which is in keeping with the widespread use of these agents. With regard to pigment nephropathy, conflicting results are found with studies showing an increase, no effect or a decrease in markers of muscle damage.
Exertional heat stroke
AKI is often found in patients with EHS, which can be fatal. In addition to rhabdomyolysis and volume depletion, alterations in circulating vasoactive mediators are implicated. Subsequent multiorgan injury results from a complex interplay between the cytotoxic effect of the heat and the inflammatory and coagulation responses of the host. There have been recent guidelines developed to reduce the risk of EHS particularly in warm environments from the perspective of the athlete (including heat acclimatisation, initiate competition in an euhydrated state and minimise dehydration) and event organisers (provide shaded areas, cooling and rehydration facilities, and suitably schedule events).

Exercise-induced AKI developing after anaerobic exercise
Exercise-induced AKI developing after anaerobic exercise (coined ALPE) is an uncommon syndrome differing from rhabdomyolysis by normal or slightly elevated serum muscle enzymes associated with muscle damage and the presence of severe loin pain. Vasoconstriction of intrarenal arteries within the kidney is thought to be the cause and studies using CT demonstrate multiple wedge-shaped areas of contrast enhancement in keeping with patchy vasoconstriction of the renal vessels. It is thought that vascular spasm accounts for the pain reported. Interestingly, a recent review of 118 cases of ALPE demonstrated a high percentage of subjects had hypouricaemia which can be associated with exercise-induced AKI.

Limitations of the study
To the authors’ knowledge this is the first systematic review to address case reports of AKI in association with endurance events and provides evidence from a number of observational studies, as to the effects of endurance events on SCr. The studies included were heterogenous (though most scored highly on a risk of bias assessment) and none included a significant time of follow-up, nor was any study found looking at the effect of performing multiple endurance events, over a period of years. Newer studies with renal biomarkers have suggested an increased SCr may be due to more than just an enhanced solute load and reduced clearance. However, firm conclusions as yet cannot be drawn from the available evidence. The case reports of significant renal injury by their retrospective nature have limitations, though the relatively large number with similar histories (acute illness, collapse, nephrotoxic drug use and delayed presentations) allows some interesting information to be drawn.
CONCLUSIONS

AKI requiring medical attention associated with extreme exercise is rare, with only 27 cases identified in this review, usually thought to be primarily due to rhabdomyolysis. Most cases had a number of risk factors for AKI, including the use of NSAIDs and an intercurrent illness or gastrointestinal upset. The majority presented in a delayed fashion, emphasising the need for awareness of this rare complication, particularly among participants who have become unwell during an event. It is likely that less severe cases of AKI with rhabdomyolysis go unreported and self-resolve. In contrast, an SCr rise after a marathon or ultra-marathon is common, with an average rise of 29 (±12.3) μmol/L, which appears to improve rapidly. However, there are few studies of collapsed runners with deranged renal function and their longer-term follow-up. Furthermore, in light of gathering evidence that strenuous exercise could have some adverse effects, it is not clear whether repeated participation in such events may eventually lead to significant long-term renal dysfunction. New biomarkers may be able to differentiate between an increased SCr due to an enhanced solute load and reduced clearance, rather than direct tubular damage. As such, their use in collapsed runners, who represent a higher-risk group, may be of future interest, as an addition to routine point-of-care testing.

RECOMMENDATIONS

Below are our pragmatic recommendations:

1. All marathon runners (or other endurance runners) should be given advice regarding the avoidance of NSAIDs, monitoring of urine volume and colour and the importance of adequate hydration.
2. Participants with pre-existing risk factors (for example, pre-existing renal dysfunction, hypertension and diabetes) should be made aware of the potential dangers of NSAIDs and systemic upset (such as vomiting) around the time of the event.
3. Runners who have collapsed during or at the end of a marathon, should have their observations recorded and basic investigations performed (including a urine dip and basic biochemistry); abnormal results should be followed up within a suitable time frame, according to local resources.
4. Future research could focus on biomarkers that more specifically reflect renal dysfunction, to help identify those at most risk and allow follow-up, where dysfunction has been found.

Contributors LH: conception, design, literature search, risk of bias assessment, write-up. EW: conception, design, literature search, write-up. RV: conception, design, literature search, write-up. RG: conception, literature search, write-up. LF: conception design, literature search, risk of bias assessment, write-up.

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


Acute kidney injury associated with endurance events—is it a cause for concern?
A systematic review

LE Hodgson, E Walter, RM Venn, R Galloway, Y Pitsiladis, F Sardat and LG Forni

BMJ Open Sport Exerc Med 2017 3:
doi: 10.1136/bmjsem-2015-000093

Updated information and services can be found at:
http://bmjopensem.bmj.com/content/3/1/e000093

These include:

References
This article cites 119 articles, 17 of which you can access for free at:
http://bmjopensem.bmj.com/content/3/1/e000093#ref-list-1

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/